← SynDRA
COBIMETINIB
SynDRA canonical compound SYN0033857 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | MAP2K1 |
|---|
| Mechanism of action | MEK inhibitor |
|---|
| Indication | melanoma |
|---|
| Disease area | oncology |
|---|
All known targets
- MAP2K1
- MAP2K2
- ACTR3
- BRAF
- KCNH2
Mechanisms of action (all sources)
- MAP2K1 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- MAP2K2 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- MEK inhibitor
Drug classes
- Kinase Inhibitors
- Kinase Inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- RG 7420
- GDC-0973
- cobimetinib butyrate
- cobimetinib fumarate
- cotellic
- XL518
- cobimetinib hemifumarate
- Gdc-0623
- Xl 518
- Xl518
- RG-7420
- RG7420
- Cotellic
- Cobimetinib fumarate
- Cobimetinib hemifumarate
- Xl-518 hemifumarate
- GDC-0973 hemifumarate
- UNII-6EXI96H8SV
- 6EXI96H8SV
- Cobimetinib fumarate [USAN]
- Cobimetinib fumarate (USAN)
- Cotellic (TN)
- CHEMBL2364607
- CHEBI:90853
- Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl)-, (2E)-2-butenedioate (2:1)
- D10615
- bis[(2S)-2-{1-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoyl]-3-hydroxyazetidin-3-yl}piperidin-1-ium] (2E)-but-2-enedioate
- GDC 0623
- UNII-HW67545I4Q
- RG 7421
- GDC0623
- HW67545I4Q
- G-868
- Imidazo[1,5-a]pyridine-6-carboxamide, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-
- 5-((2-FLUORO-4-IODOPHENYL)AMINO)-N-(2-HYDROXYETHOXY)IMIDAZO[1,5-A]PYRIDINE-6-CARBOXAMIDE
- RFWVETIZUQEJEF-UHFFFAOYSA-N
- GTPL9909
- SCHEMBL1615104
Reported adverse events
- Chills
- Dry skin
- Fatigue
- Hypertension
- Nausea
- Pneumonitis
- Pruritus
- Pyrexia
- Rhabdomyolysis
- Stomatitis
- Vomiting
- Acne
Look up COBIMETINIB in the interactive SynDRA portal →